Pharmacogenetic treatments for drug addiction: cocaine, amphetamine and methamphetamine.
about
Toxicity of amphetamines: an updatePharmacotherapy for stimulant-related disordersPharmacotherapy of amphetamine-type stimulant dependence: an updateLow dopamine function in attention deficit/hyperactivity disorder: should genotyping signify early diagnosis in children?The neurocircuitry of illicit psychostimulant addiction: acute and chronic effects in humansMethamphetamine enhances paced mating behaviors and neuroplasticity in the medial amygdala of female ratsGenetic association of GABA-A receptor alpha-2 and mu opioid receptor with cocaine cue-reactivity: evidence for inhibitory synaptic neurotransmission involvement in cocaine dependence.Placebo-group responders in methamphetamine pharmacotherapy trials: the role of immediate establishment of abstinence.AMPA receptor synaptic plasticity induced by psychostimulants: the past, present, and therapeutic futureRetrotransposition of long interspersed element 1 induced by methamphetamine or cocaine.Attenuation of cocaine-induced locomotor activity in male and female mice by active immunization.Cigarette smoking and short-term addiction treatment outcome.A double-blind, placebo-controlled assessment of the safety of potential interactions between intravenous cocaine, ethanol, and oral disulfiram.The influence of dopamine receptor d4 polymorphism on resting EEG in healthy young femalesClinical features, course and treatment of methamphetamine-induced psychosis in psychiatric inpatientsAddiction pharmacogenetics: a systematic review of the genetic variation of the dopaminergic systemToward biomarkers of the addicted human brain: Using neuroimaging to predict relapse and sustained abstinence in substance use disorder.Androgen-primed castrate males are sufficient for methamphetamine-facilitated increases in proceptive behavior in female ratsEnhanced extinction of cocaine seeking in brain-derived neurotrophic factor Val66Met knock-in miceGene x abstinence effects on drug cue reactivity in addiction: multimodal evidenceRivastigmine reduces "Likely to use methamphetamine" in methamphetamine-dependent volunteers.The κ-opioid receptor gene as a predictor of response in a cocaine vaccine clinical trial.Transcriptional modulation of monoaminergic neurotransmission genes by the histone deacetylase inhibitor trichostatin A in neuroblastoma cells.Medications for substance use disorders (SUD): emerging approaches.Serotonin and Dopamine Candidate Gene Variants and Alcohol- and Non-Alcohol-Related Aggression.Polymorphisms of COMT Val158Met and DAT1 3'-UTR VNTR in illicit drug use and drug-related psychiatric disorders.Effects of cigarette smoking and alcohol use on neurocognition and BDNF levels in a Chinese population.Prenatal amphetamine exposure effects on dopaminergic receptors and transporter in postnatal rats.The potential of pharmacogenomics to treat drug addiction.
P2860
Q22252794-DBF18672-65AD-4E6B-BEB8-97BD91C4B8E9Q26829186-58CD3BB7-EF8E-49E5-B027-276147A14CA4Q26991936-DCD34C4C-A317-416D-811A-17E2C4F23B63Q27026214-0D702F8B-FFF3-431B-BF7B-4E424B4C001BQ28236333-DE1C7733-EF6B-4B49-903D-93F479B78AF1Q28578936-AB98C9D0-FC92-4DF5-92AC-1D56A1CA4126Q30524334-6D304A4A-DC0E-468B-9DD9-3A71A333B7F5Q33671505-9C85D952-753A-4B4A-8E46-3F4C54674AC3Q33995795-6694831D-620E-44BC-AE43-2DD6CBBB4119Q34170616-921ABA34-C669-40CA-B133-65A851621808Q34287658-3B44C6C7-3D33-4EE8-BEC0-27B43C5FA1FCQ34827624-DD16D35A-A0B4-4970-B102-E3C947A49A89Q35489643-AA804E4D-A48C-409E-ABC7-C94793EF69E0Q35841115-6F5ADEBB-8E96-4D3F-952F-6F366127C63CQ35934610-853E7B3E-01BC-4930-9020-973FB563E581Q35995415-18B59ECE-2070-4201-B1BE-C0F7408A91EDQ36316106-335633FC-9648-4158-9A6D-D463909AF968Q36479464-E7CF9121-ABF4-4E50-8052-540FD97BC5DDQ36765712-C2BB1BF2-7758-4A05-BE0E-BC71AAF566B2Q36928468-A28F45A7-4039-4EE5-92C1-45B4E3CBD43DQ37425104-90958086-9D2A-4994-903E-6AA36CD697ADQ37453915-8E5DA735-1387-4B56-A1CE-17716325C1A9Q39501491-A11E18FB-C6A4-436E-9DFC-C3F87A2E23C9Q47731975-A9AC90F8-A34E-46C1-AB0F-18B189F380E6Q48081384-54557060-6DF2-46AF-9A5C-83892237DD91Q48318550-A92CD92F-9431-4F8C-A4F2-04BB739EC46FQ50552056-21B8FF2C-A7C7-41B6-BF7E-9617EB439AC9Q51459211-191081B4-ED3B-45B9-AC80-ACE419851C48Q52295623-7AF968EF-2653-46A3-8868-06A205CE3E88
P2860
Pharmacogenetic treatments for drug addiction: cocaine, amphetamine and methamphetamine.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Pharmacogenetic treatments for drug addiction: cocaine, amphetamine and methamphetamine.
@ast
Pharmacogenetic treatments for drug addiction: cocaine, amphetamine and methamphetamine.
@en
Pharmacogenetic treatments for drug addiction: cocaine, amphetamine and methamphetamine.
@nl
type
label
Pharmacogenetic treatments for drug addiction: cocaine, amphetamine and methamphetamine.
@ast
Pharmacogenetic treatments for drug addiction: cocaine, amphetamine and methamphetamine.
@en
Pharmacogenetic treatments for drug addiction: cocaine, amphetamine and methamphetamine.
@nl
prefLabel
Pharmacogenetic treatments for drug addiction: cocaine, amphetamine and methamphetamine.
@ast
Pharmacogenetic treatments for drug addiction: cocaine, amphetamine and methamphetamine.
@en
Pharmacogenetic treatments for drug addiction: cocaine, amphetamine and methamphetamine.
@nl
P2093
P2860
P1476
Pharmacogenetic treatments for drug addiction: cocaine, amphetamine and methamphetamine.
@en
P2093
Colin N Haile
Therese A Kosten
Thomas R Kosten
P2860
P304
P356
10.1080/00952990902825447
P577
2009-01-01T00:00:00Z